Literature DB >> 12409333

Immunomagnetic enrichment and detection of micrometastases in colorectal cancer: correlation with established clinical parameters.

Martin R Weihrauch1, Edmund Skibowski, Thomas C Koslowsky, Wilfried Voiss, Daniel Re, Ferdinand Kuhn-Regnier, Carolin Bannwarth, Michel Siedek, Volker Diehl, Heribert Bohlen.   

Abstract

PURPOSE: Micrometastatic disease in bone marrow is of prognostic significance in colorectal cancer patients. However, detection rates of standard immunocytology are relatively low. We used magnetic activated cell sorting (MACS), a highly sensitive method, to increase detection rates and correlated the presence of cytokeratin (CK)-expressing cells with clinical parameters. PATIENTS AND METHODS: Bone marrow was obtained from 51 consecutive patients with newly diagnosed colorectal adenocarcinoma who underwent primary surgery and 18 control subjects. International Union Against Cancer (UICC) stage I disease was diagnosed in 11 patients, stage II disease was diagnosed in 14 patients, stage III disease was diagnosed in 12 patients, and stage IV disease was diagnosed in 14 patients. CK-positive cells were enriched and stained with magnetically labeled CAM 5.2 antibodies directed to CK 7 and 8.
RESULTS: CK-positive cells were found in 33 (65%) patients and were absent in 18 (35%). Four of 11 (36%) patients with UICC stage I disease, nine of 14 (64%) with stage II diease, eight of 12 (67%) with stage III disease, and 12 of 14 (86%) with stage IV disease were CK-positive. Epithelial cells were more frequently found in pT3/4 (72%) than in pT1/2 (36%) tumors (P =.026), but there was no difference for lymph node status. CK-positive patients had a higher chance for elevated carcinoembryonic antigen (85% v 15%, P = NS) and CA 19-9 levels (92% v 8%, P =.019). There were no significant differences in CA 72-4, sex, age, tumor grading, or tumor localization regarding the presence of CK-positive cells. All control subjects were CK-negative.
CONCLUSION: In searching for micrometastases in colorectal cancer patients, we have achieved high detection rates by using MACS. The presence of these cells correlated significantly with tumor stage, tumor extension, and the tumor marker CA 19-9.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409333     DOI: 10.1200/JCO.2002.02.152

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  A rare-cell detector for cancer.

Authors:  Robert T Krivacic; Andras Ladanyi; Douglas N Curry; H B Hsieh; Peter Kuhn; Danielle E Bergsrud; Jane F Kepros; Todd Barbera; Michael Y Ho; Lan Bo Chen; Richard A Lerner; Richard H Bruce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

2.  Clinical significance of telomerase activity in peritoneal disseminated cells: gastrointestinal cancers.

Authors:  Inna L Botchkina; David E Rivadeneira; Kevin Watkins; Martin S Karpeh; Galina I Botchkina
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

3.  Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.

Authors:  M V Croce; M Isla-Larrain; R Tur; M E Rabassa; A Segal-Eiras
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 4.  Approaches to isolation and molecular characterization of disseminated tumor cells.

Authors:  Mark Jesus M Magbanua; Rishi Das; Prithi Polavarapu; John W Park
Journal:  Oncotarget       Date:  2015-10-13

5.  Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.

Authors:  Xi Chen; Xu Wang; Hua He; Ziling Liu; Ji-Fan Hu; Wei Li
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

6.  Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival.

Authors:  Carsten T Viehl; Benjamin Weixler; Ulrich Guller; Salome Dell-Kuster; Rachel Rosenthal; Michaela Ramser; Vanessa Banz; Igor Langer; Luigi Terracciano; Guido Sauter; Daniel Oertli; Markus Zuber
Journal:  Cancer Med       Date:  2017-04-12       Impact factor: 4.452

7.  Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection.

Authors:  Lili Wang; Yanyan Wang; Yajing Liu; Min Cheng; Xu Wu; Haiming Wei
Journal:  J Exp Clin Cancer Res       Date:  2009-04-28

8.  Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance.

Authors:  Valérie Choesmel; Jean-Yves Pierga; Claude Nos; Anne Vincent-Salomon; Brigitte Sigal-Zafrani; Jean-Paul Thiery; Nathalie Blin
Journal:  Breast Cancer Res       Date:  2004-07-29       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.